JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 145-151

  Kiziltepe, Tanyel ^a   Anderson, Kenneth C ^a   Kutok, Jeffery L ^b   Jia, Lee ^c   Boucher, Kenneth M ^d   Saavedra, Joseph E ^e   Keefer, Larry K ^f   Shami, Paul J ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e SAIC FREDERICK INC   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; HUVEC; JS K; Myeloma; Nitric oxide

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; O2 (2,4 DINITROPHENYL) 1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; PRODRUG; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CHICK; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH STIMULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE CANCER; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; UMBILICAL VEIN; VASCULAR RING;

EID: 77949494329     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0017     Document Type: Article

References (25)

1. Magrinat G et al. Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood 1992; 80: 1880-1884.
2. Shami PJ et al. Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leuk Res 1995; 19: 527-533.
3. Shami PJ et al. Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide. Leukemia 1998; 12: 1461-1466.
4. Moncada S et al. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
5. Shami PJ et al. JS-K, a glutathione S-transferase-activated nitric oxide donor with potent anti-neoplastic activity. Mol Cancer Ther 2003; 2: 409-417.
6. Baines P et al. Multidrug resistance in leukaemia. Baillieres Clin Hematol 1992; 5: 943-960.
7. Sargent JM et al. Evidence for the involvement of the glutathione pathway in drug resistance in AML. Adv Exp Med Biol 1999; 457: 205-209.
8. Kiziltepe T et al. JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in human multiple myeloma cells. Blood 2007; 110: 709-718.
9. NAr reactions. J Org Chem 2001; 66: 3090-3098.
10. Kaur G et al. Antiangiogenic properties of 17- (dimethylaminoethylamino)-17-demethoxy-geldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004; 10: 4813-4821.
11. Auerbach R et al. Angiogenesis assays: a critical overview. Clin Chem 2003; 49: 32-40.
12. de Vos FY et al. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev 2004; 30: 495-513.
13. Bruneel A et al. Proteomic study of human umbilical vein endothelial cells in culture. Proteomics 2003; 3: 714-723.
14. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-3064.
15. Kimura H et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000; 95: 189-197.
16. Pipili-Synetos E et al. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994; 111: 894-902.
17. Jia L et al. Anti-angiogenetic effects of S-nitrosocaptopril crystals as a nitric oxide donor. Eur J Pharmacol 2000; 391: 137-144.
18. Shami PJ et al. Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics 2009; 94: 32-38.
19. Cohen SD, Khairallah EA. Selective protein arylation and acetaminophen-induced hepatotoxicity. Drug Metab Rev 1997; 29: 59-77.
20. 2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 2006; 49: 4356-4366.
21. Townsend DM et al. A glutathione S-transferase p-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol 2006; 69: 501-508.
22. Mieyal JJ et al. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxidants Redox Signaling 2008; 10: 1941-1988.
23. Podar K et al. Best practice and research. The malignant clone and the bone-marrow environment. Clin Haematol 2007; 20: 597-612.
24. Rajkumar SV et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116.
25. Kumar S et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004; 34: 235-239.